Anette Løken Eilertsen

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis
    Anette Løken Eilertsen
    Department of Hematology, Faculty Division, Ullevaal University Hospital, Oslo, Norway
    Maturitas 52:111-8. 2005
  2. ncbi Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation
    A L Eilertsen
    Department of Hematology, Ullevaal University Hospital Trust, Hematological Research Laboratory, NO 0407 Oslo, Norway
    Maturitas 55:278-87. 2006
  3. ncbi Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis
    Anette Løken Eilertsen
    Department of Hematology, Ulleval University Hospital Trust, Oslo, Norway
    Thromb Res 120:371-9. 2007
  4. ncbi Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system
    Anette L Eilertsen
    Department of Haematology Ullevål University Hospital Trust, Oslo, Norway
    Thromb Haemost 97:938-43. 2007
  5. ncbi Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method
    A L Eilertsen
    Department of Haematology and Faculty Division, Ulleval University Hospital Trust, Oslo, Norway
    BJOG 115:773-9. 2008
  6. ncbi Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers
    A L Eilertsen
    Department of Haematology, Ulleval University Hospital Trust, Oslo, and Faculty Division Ullevål University Hospital, Oslo, Norway
    J Thromb Haemost 6:928-34. 2008
  7. ncbi Mechanisms of thrombosis related to hormone therapy
    Per Morten Sandset
    Oslo University Hospital at Ullevål, Department of Hematology, Oslo, Norway Faculty of Medicine, University of Oslo, Oslo, Norway
    Thromb Res 123:S70-3. 2009

Detail Information

Publications7

  1. ncbi The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis
    Anette Løken Eilertsen
    Department of Hematology, Faculty Division, Ullevaal University Hospital, Oslo, Norway
    Maturitas 52:111-8. 2005
    ..No such associations were observed in the estrogen women atherosclerosis (EWA) study of 118 women with established coronary artery disease who were given transdermal HRT...
  2. ncbi Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation
    A L Eilertsen
    Department of Hematology, Ullevaal University Hospital Trust, Hematological Research Laboratory, NO 0407 Oslo, Norway
    Maturitas 55:278-87. 2006
    ..We have compared the effects of estrogen, tibolone, and raloxifene on relevant markers of coagulation activation and investigated whether there is a dose-response relationship of oral HT...
  3. ncbi Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis
    Anette Løken Eilertsen
    Department of Hematology, Ulleval University Hospital Trust, Oslo, Norway
    Thromb Res 120:371-9. 2007
    ..The aim of this study was to elucidate the mechanism(s) for differences in coagulation activation by analysing clotting and fibrinolytic factors and coagulation inhibitors...
  4. ncbi Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system
    Anette L Eilertsen
    Department of Haematology Ullevål University Hospital Trust, Oslo, Norway
    Thromb Haemost 97:938-43. 2007
    ..Our findings indicate that oestrogen-progestin therapy induces an APC resistant phenotype, which may be related to dose, whereas tibolone and raloxifene only marginally alter the sensitivity to APC...
  5. ncbi Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method
    A L Eilertsen
    Department of Haematology and Faculty Division, Ulleval University Hospital Trust, Oslo, Norway
    BJOG 115:773-9. 2008
    ..To evaluate impact of different postmenopausal hormone therapy (HT) regimens and raloxifene on mammographic breast density...
  6. ncbi Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers
    A L Eilertsen
    Department of Haematology, Ulleval University Hospital Trust, Oslo, and Faculty Division Ullevål University Hospital, Oslo, Norway
    J Thromb Haemost 6:928-34. 2008
    ..Postmenopausal hormone therapy (HT) is associated with an increased risk for arterial and venous thrombosis...
  7. ncbi Mechanisms of thrombosis related to hormone therapy
    Per Morten Sandset
    Oslo University Hospital at Ullevål, Department of Hematology, Oslo, Norway Faculty of Medicine, University of Oslo, Oslo, Norway
    Thromb Res 123:S70-3. 2009
    ..Coagulation markers should be used as intermediate or surrogate markers in early pharmacodynamic studies to evaluate the risk associated with new formulations...